Overview

CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)

Status:
Completed
Trial end date:
2020-04-21
Target enrollment:
Participant gender:
Summary
The objective of the study is to compare the efficacy and safety of 3 doses CS02 Tablet in combination with a stable dose of metformin monotherapy against CS02 PTM (placebo) Tablet in combination with a stable dose of metformin monotherapy over a 12 weeks treatment period in subjects with type 2 diabetes mellitus with inadequate glycemic control on metformin alone.
Phase:
Phase 2
Details
Lead Sponsor:
Center Laboratories, Inc.
Treatments:
Metformin